Trial Profile
prospective observational study to assess efficacy and safety of nivolumab in patients with recurrent non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Jul 2016 New trial record